A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats

被引:114
作者
Million, M [1 ]
Grigoriadis, DE
Sullivan, S
Crowe, PD
McRoberts, JA
Zhou, HP
Saunders, PR
Maillot, C
Mayer, EA
Taché, Y
机构
[1] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA
[2] Univ Calif Los Angeles, W Los Angeles VA Med Ctr, Ctr Neurovisceral Sci & Womens Hlth, Div Digest Dis,Dept Med, Los Angeles, CA 90073 USA
[3] Neurocrine Biosci Inc, San Diego, CA 92121 USA
关键词
non-peptide receptor antagonist; CRF1; receptor; colonic transit; colorectal distention; visceral pain;
D O I
10.1016/S0006-8993(03)03027-0
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
The stress response involves the activation of two corticotropin-releasing factor (CRF) receptor subtypes. We investigated the role of CRF, in stress-related visceral responses. A novel water-soluble tricyclic CRF, antagonist, NBI 35965 was developed that displayed a high affinity for CRF1 (K(i)similar to4 nM) while having no binding affinity to CRF2. This antagonist also inhibited the stimulation of cAMP induced by sauvagine in CRF1 transfected cells. NBI 35965 administered per orally (p.o.) in rats (1, 3, 10 or 30 mg/kg) inhibited dose-dependently [I-125] sauvagine binding selectively at brain sites of CRF, distribution as shown by ex vivo receptor autoradiography. At the highest doses, NBI 35965 completely prevented [I-125]sauvagine labeling in the cortex. NBI 35965 (10 mg/kg) administered p.o. or subcutaneously (sc) 1 h before intravenous CRF completely blocked the 81% shortening of distal colonic transit time induced by CRF. NBI 35965 (20 mg/kg s.c.) significantly reduced the defecation in response to water avoidance stress but not that induced by s.c. carbachol. In adult male Long-Evans rats that had undergone maternal separation, acute water avoidance stress significantly increased the visceromotor response to colorectal distention (20-80 mmHg) by 42+/-19% compared with the response before stress. Stress-induced visceral hyperalgesia was abolished by NBI 35965 (20 mg/kg, s.c.). The data show that NBI 35965 is a novel water-soluble selective CRF, antagonist with bioavailability to the brain upon peripheral administration and that CRF1 receptor signaling pathways are involved in water avoidance stress-induced hyperalgesia to colorectal distention and stimulation of colonic transit. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:32 / 42
页数:11
相关论文
共 54 条
[1]
Behan DP, 1996, MOL PSYCHIATR, V1, P265
[2]
WATER-AVOIDANCE STRESS-INDUCED C-FOS EXPRESSION IN THE RAT-BRAIN AND STIMULATION OF FECAL OUTPUT - ROLE OF CORTICOTROPIN-RELEASING FACTOR [J].
BONAZ, B ;
TACHE, Y .
BRAIN RESEARCH, 1994, 641 (01) :21-28
[3]
Acute stress causes mucin release from rat colon: Role of corticotropin releasing factor and mast cells [J].
Castagliuolo, I ;
LaMont, JT ;
Qiu, BS ;
Fleming, SM ;
Bhaskar, KR ;
Nikulasson, ST ;
Kornetsky, C ;
Pothoulakis, C .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1996, 271 (05) :G884-G892
[4]
Chen C, 1996, J MED CHEM, V39, P4358
[5]
COUNTINHO SV, 2002, AM J PHYSIOL-GASTR L, V282, pG307
[6]
Creed Francis, 1999, American Journal of Medicine, V107, p74S
[7]
Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome [J].
Fukudo, S ;
Nomura, T ;
Hongo, M .
GUT, 1998, 42 (06) :845-849
[8]
Involvement of corticotropin-releasing factor receptor subtype 1 in morphine withdrawal regulation of the brain noradrenergic system [J].
Funada, M ;
Hara, C ;
Wada, K .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 430 (2-3) :277-281
[9]
Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs [J].
Gabry, KE ;
Chrousos, GP ;
Rice, KC ;
Mostafa, RM ;
Sternberg, E ;
Negrao, AB ;
Webster, EL ;
McCann, SM ;
Gold, PW .
MOLECULAR PSYCHIATRY, 2002, 7 (05) :474-483
[10]
Corticotropin releasing factor (CRF) receptor modulators: Progress and opportunities for new therapeutic agents [J].
Gilligan, PJ ;
Robertson, DW ;
Zaczek, R .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (09) :1641-1660